Reports
Sale
Global Dravet Syndrome Treatment Market Size, Trends, Growth, Analysis: By Seizures Type: Myoclonic Seizures, Atonic Seizures, Partial Seizures, Absence Seizures, Tonic Seizures, Photosensitive Seizures, Others; By Diagnosis Type; By Treatment Type; By End User; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Global Dravet Syndrome Treatment Market Outlook
The global Dravet syndrome treatment market size attained a value of USD 0.36 billion in 2023. The market is likely to expand at a CAGR of 10.10% during the forecast period of 2024-2032 to attain a value of USD 0.86 billion by 2032. The growth of the market is being driven by the rising prevalence of the condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Dravet Syndrome Treatment Market: Introduction
Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare, severe form of epilepsy that starts in infancy. It is a genetic disorder caused by mutations in the SCN1A gene. There is currently no cure for Dravet Syndrome, but there are various treatment options available that aim to manage the symptoms of the disease. The report covers the market for Dravet Syndrome treatment, including drugs and therapies, and provides a detailed analysis of the market size, growth, and trends.
Dravet Syndrome Epidemiology
Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare genetic disorder that affects approximately one in every 15,700 individuals worldwide. The disease typically begins in infancy, with infants experiencing seizures that are often prolonged and difficult to manage. As the child grows, the seizures may become more frequent and severe, and may be accompanied by cognitive and behavioral problems.
The prevalence of Dravet Syndrome varies by region, but it is estimated to affect approximately one in every 20,000 to 40,000 individuals worldwide. It is more common in males than females, with a male-to-female ratio of approximately 1.5:1.
The treatment options for Dravet Syndrome are focused on managing the symptoms of the disease and improving the quality of life of patients. The primary treatment is medication, specifically anticonvulsants such as clobazam, valproate, and stiripentol. These drugs work by stabilizing the electrical activity in the brain, reducing the frequency and severity of seizures. Benzodiazepines may also be used in combination with anticonvulsants to manage acute seizures.
DRAVET SYNDROME TREATMENT Market Segmentations
The market can be categorised into seizure type, diagnosis type, treatment type, end user, and major region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Seizures Type
- Myoclonic Seizures
- Atonic Seizures
- Partial Seizures
- Absence Seizures
- Tonic Seizures
- Photosensitive Seizures
- Others
Market Breakup by Diagnosis Type
- Magnetic Resonance Imaging
- Electroencephalography
- SCN1 A Testing
- Others
Market Breakup by Treatment Type
- Seizure Medications
- Ketogenic Diet
- Vagus Nerve Stimulation
- Others
Market Breakup by End User
- Pharmaceutical Companies
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Dravet Syndrome Treatment Market Scenario
The global Dravet syndrome treatment market is expected to grow at a significant rate during the forecast period of 2024-2032. The increasing prevalence of the disease, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.
North America dominates the Dravet Syndrome treatment market, followed by Europe and Asia Pacific. The high prevalence of Dravet Syndrome in North America, coupled with the favorable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for Dravet Syndrome treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
Key Players in the Global Dravet Syndrome Treatment Market
The report gives an in-depth analysis of the key players involved in the Dravet Syndrome Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Biocodex
- Biscayne Neurotherapeutics (Supernus Pharmaceuticals, Inc.)
- Cyberonics (LivaNova PLC)
- Epygenix Therapeutics, Inc.
- GW Pharmaceuticals (Jazz Pharmaceuticals, Inc.)
- OPKO Health, Inc.
- Ovid Therapeutics
- PTC Therapeutics
- Encoded Therapeutics, Inc.
- Zogenix (UCB S.A., Belgium)
- Takeda Pharmaceutical Company Limited
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Seizures Type |
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
|
Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Global Dravet Syndrome Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Dravet Syndrome Treatment Market
8.1 Global Dravet Syndrome Treatment Market Overview
8.2 Global Dravet Syndrome Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Dravet Syndrome Treatment Market Historical Value (2017-2023)
8.2.1.2 Global Dravet Syndrome Treatment Market Forecast Value (2024-2032)
8.2.2 Global Dravet Syndrome Treatment Market by Seizures Type
8.2.2.1 Market Overview
8.2.2.1.1 Myoclonic Seizures
8.2.2.1.2 Atonic Seizures
8.2.2.1.3 Partial Seizures
8.2.2.1.4 Absence Seizures
8.2.2.1.5 Tonic Seizures
8.2.2.1.6 Photosensitive Seizures
8.2.2.1.7 Others
8.2.3 Global Dravet Syndrome Treatment Market by Diagnosis Type
8.2.3.1 Market Overview
8.2.3.1.1 Magnetic Resonance Imaging
8.2.3.1.2 Electroencephalography
8.2.3.1.3 Scn1 A Testing
8.2.3.1.4 Others
8.2.4 Global Dravet Syndrome Treatment Market by Treatment Type
8.2.4.1 Market Overview
8.2.4.1.1 Seizure Medications
8.2.4.1.2 Ketogenic Diet
8.2.4.1.3 Vagus Nerve Stimulation
8.2.4.1.4 Others
8.2.5 Global Dravet Syndrome Treatment Market by End User
8.2.5.1 Market Overview
8.2.5.1.1 Pharmaceutical Companies
8.2.5.1.2 Hospitals
8.2.5.1.3 Diagnostic Laboratories
8.2.5.1.4 Academic and Research Institutes
8.2.5.1.5 Others
8.2.6 Global Dravet Syndrome Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Dravet Syndrome Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Dravet Syndrome Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Dravet Syndrome Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Dravet Syndrome Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Dravet Syndrome Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Dravet Syndrome Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Biocodex
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Biscayne Neurotherapeutics (Supernus Pharmaceuticals, Inc.)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Cyberonics (LivaNova PLC)
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Epygenix Therapeutics, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 GW Pharmaceuticals (Jazz Pharmaceuticals, Inc.)
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 OPKO Health, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Ovid Therapeutics
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 PTC Therapeutics
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Encoded Therapeutics, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Zogenix (UCB S.A., Belgium)
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Takeda Pharmaceutical Company Limited
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Dravet Syndrome Treatment Market Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 0.36 billion in 2023.
The market is likely to expand at a CAGR of 10.10% during the forecast period of 2024-2032 to attain a value of USD 0.86 billion by 2032.
The market is primarily driven by the rising prevalence of chronic disorders, increasing research and developmental activities, robust clinical products pipeline and favouring government initiatives.
North America is anticipated to hold a maximum share of the market during the forecast period.
Based on the seizure type, the market is segmented into myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic seizures, photosensitive seizures, and others.
Based on the diagnosis type, the market is bifurcated into Magnetic Resonance Imaging (MRI), electroencephalography, Scn1 A testing, and others.
Based on the end users, the market is divided into pharmaceutical companies, hospitals, diagnostic laboratories, academic & research institutes, and others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in the market are Biocodex, Biscayne Neurotherapeutics (Supernus Pharmaceuticals, Inc.), Cyberonics (LivaNova PLC), Epygenix Therapeutics, Inc., GW Pharmaceuticals (Jazz Pharmaceuticals, Inc.), OPKO Health, Inc., Ovid Therapeutics, PTC Therapeutics, Encoded Therapeutics, Inc., Zogenix (UCB S.A., Belgium), and Takeda Pharmaceutical Company Limited, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER